Liver Failure - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Failure - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Liver Failure - Pipeline Review, H1 2015', provides an overview of the Liver Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
Pipeline Products for Liver Failure - Overview 8
Pipeline Products for Liver Failure - Comparative Analysis 9
Liver Failure - Therapeutics under Development by Companies 10
Liver Failure - Therapeutics under Investigation by Universities/Institutes 11
Liver Failure - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Liver Failure - Products under Development by Companies 15
Liver Failure - Products under Investigation by Universities/Institutes 16
Liver Failure - Companies Involved in Therapeutics Development 17
Alfact Innovation 17
Conatus Pharmaceuticals Inc. 18
Digna Biotech, S.L. 19
Grifols, S.A. 20
Immune Pharmaceuticals, Ltd. 21
Ventria Bioscience 22
Liver Failure - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
albumin (human) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ALF-5755 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BI-78D3 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cardiotrophin-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy for Liver Failure - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
emricasan - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
F-573 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ImmuneSafe - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Oligonucleotide for Liver Failure - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Recombinant Protein for Liver Failure - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Stem Cell Therapy for Liver Failure - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VEN-100 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Liver Failure - Recent Pipeline Updates 51
Liver Failure - Dormant Projects 56
Liver Failure - Product Development Milestones 57
Featured News & Press Releases 57
Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 57
Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 59
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 59
Apr 02, 2013: ALF-5755 phase II completion 60
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 60
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 61
May 06, 2011: ALF-5755 phase II extends to germany 62
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 62
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 62
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for Liver Failure, H1 2015 8
Number of Products under Development for Liver Failure - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Liver Failure - Pipeline by Alfact Innovation, H1 2015 17
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 18
Liver Failure - Pipeline by Digna Biotech, S.L., H1 2015 19
Liver Failure - Pipeline by Grifols, S.A., H1 2015 20
Liver Failure - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 21
Liver Failure - Pipeline by Ventria Bioscience, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Liver Failure Therapeutics - Recent Pipeline Updates, H1 2015 51
Liver Failure - Dormant Projects, H1 2015 56